UNICA IRIS Institutional Research Information System

CARTA, ANNAROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 158.991
NA - Nord America 8.405
AS - Asia 3.783
SA - Sud America 594
Continente sconosciuto - Info sul continente non disponibili 348
AF - Africa 120
OC - Oceania 40
Totale 172.281
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 156.840
US - Stati Uniti d'America 8.241
SG - Singapore 1.361
CN - Cina 1.342
UA - Ucraina 526
BR - Brasile 459
SE - Svezia 441
VN - Vietnam 285
DE - Germania 259
FI - Finlandia 230
GB - Regno Unito 228
FR - Francia 190
HK - Hong Kong 180
KR - Corea 108
CA - Canada 98
IN - India 93
BD - Bangladesh 75
AR - Argentina 50
ES - Italia 47
NL - Olanda 45
JP - Giappone 40
RU - Federazione Russa 39
IQ - Iraq 35
MX - Messico 32
PL - Polonia 32
AU - Australia 31
ZA - Sudafrica 29
TR - Turchia 28
IR - Iran 27
ID - Indonesia 25
CO - Colombia 21
PK - Pakistan 20
EC - Ecuador 19
EG - Egitto 19
UZ - Uzbekistan 19
AT - Austria 18
IE - Irlanda 17
VE - Venezuela 17
BE - Belgio 16
IL - Israele 16
KE - Kenya 16
OM - Oman 15
CL - Cile 14
JM - Giamaica 14
SA - Arabia Saudita 14
MY - Malesia 12
PH - Filippine 12
MA - Marocco 10
TN - Tunisia 10
CY - Cipro 9
GH - Ghana 9
LT - Lituania 9
NZ - Nuova Zelanda 9
TH - Thailandia 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
CZ - Repubblica Ceca 7
DZ - Algeria 7
AL - Albania 6
AZ - Azerbaigian 6
KZ - Kazakistan 6
NP - Nepal 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
CH - Svizzera 5
ET - Etiopia 5
EU - Europa 5
GR - Grecia 5
PY - Paraguay 5
HR - Croazia 4
MU - Mauritius 4
UY - Uruguay 4
BO - Bolivia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
LB - Libano 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SV - El Salvador 3
AM - Armenia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NI - Nicaragua 2
NO - Norvegia 2
AG - Antigua e Barbuda 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
Totale 171.921
Salva come PNG Salva come JPEG
Città #
Cagliari 152.674
Uta 3.579
Fairfield 816
Singapore 742
Ashburn 619
Woodbridge 588
Chandler 496
San Jose 472
Houston 396
Seattle 352
Boardman 349
Wilmington 342
Ann Arbor 327
Dallas 317
Nyköping 291
Jacksonville 283
Beijing 269
Cambridge 266
Dearborn 207
Santa Clara 137
Helsinki 136
Hong Kong 135
Los Angeles 127
Shanghai 113
New York 111
Council Bluffs 110
The Dalles 102
Nanjing 99
Hangzhou 94
Lauterbourg 94
Hefei 92
Seoul 88
Ho Chi Minh City 87
Boston 85
San Diego 64
Hanoi 63
Buffalo 60
Milan 55
Guangzhou 42
Orem 42
Toronto 36
Nanchang 30
São Paulo 30
Shenyang 29
Changsha 28
Redwood City 28
Atlanta 27
Frankfurt am Main 27
London 27
Chicago 26
Redondo Beach 26
Brooklyn 24
Munich 24
Tokyo 24
Norwalk 23
Mountain View 22
Rome 22
Dong Ket 20
Hebei 20
Jinan 19
Tianjin 19
Barcelona 18
Montreal 18
Sassari 18
Tashkent 18
Amsterdam 17
Verona 17
Warsaw 17
Brussels 16
Jiaxing 16
Assèmini 15
Nuremberg 15
Phoenix 14
San Mateo 14
Belo Horizonte 13
Rio de Janeiro 13
Zhengzhou 13
Chennai 12
Da Nang 12
Dublin 12
Johannesburg 12
Kingston 12
San Francisco 12
Washington 12
Augusta 11
Baghdad 11
Nairobi 11
Naples 11
Orange 11
Philadelphia 11
Poplar 11
Biên Hòa 10
Brasília 10
Cairo 10
Columbus 10
Denver 10
Haiphong 10
Miami 10
Pune 10
Stockholm 10
Totale 166.355
Salva come PNG Salva come JPEG
Nome #
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease 5.351
Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita 4.630
null 4.110
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice 3.839
Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease 3.711
The MPTP/probenecid model of progressive Parkinson's disease 3.525
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease 3.466
Role of Adenosine in the basal Ganglia 3.368
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.260
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.181
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 3.021
Microglial phenotypes in Parkinson's disease and animal models of the disease 3.013
Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders 2.983
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function 2.945
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? 2.861
L-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? 2.798
L dopa chronic treatment increases reactive microglia and tnf- alpha production in the 6-ohda lesioned striatum 2.712
Modulating microglia activity with PPAR-gamma agonists: a promising therapy for Parkinson's disease? 2.639
null 2.592
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats 2.561
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease 2.515
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.501
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.425
Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats 2.288
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.241
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease 2.211
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.100
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.100
The interrelationship between dopamine and noradrenaline in the prefrontal cortex: From physiology to therapy 2.010
SELECTIVE CHANGES IN DENDRITIC SPINES OF STRIATAL MEDIUM SPINY NEURONS IN A CHRONIC MOUSE MODEL OF PARKINSON'S DISEASE. 2.006
The role of microglia–lymphocyte interaction in PD neuropathology 2.002
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.954
PPAR-γ: Therapeutic Prospects in Parkinson's Disease. 1.901
Dyskinesia in Parkinson's disease therapy 1.881
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.878
null 1.857
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.834
Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species 1.782
Microglial phagocytosis and its regulation: A therapeutic target in parkinson’s disease? 1.720
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.659
null 1.651
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease 1.640
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.562
Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model 1.542
Controversie: Priming dopaminergico nel Parkinson. Il "priming" come modello sperimentale delle discinesie indotte da terapie dopaminergiche sostitutive nella Malattia di Parkinson 1.532
Can pioglitazone be potentially useful therapeutically in treating patients with Covid-19? 1.399
Long-term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress 1.318
Adenosine signaling in the basal ganglia 1.310
Caffeine sensitization and cross-sensitization with amphetamine: association to post-synaptic changes in rat striatal neurons 1.249
Metabolomics fingerprint induced by the intranigral inoculation of exogenous human alpha-synuclein oligomers in a rat model of Parkinson’s disease 1.212
null 1.194
The 6-hydroxydopamine model of Parkinson's disease 1.190
The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications 1.182
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.179
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.178
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.174
Modeling Parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers 1.149
Dopamine and adenosine receptor interaction as the basis for the treatment of Parkinson's disease 1.127
null 1.108
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression 1.096
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 1.080
Adenosine A2A receptors and Parkinson's disease 1.076
CAFFEINE SESITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST-SYNAPTIC CHANGES IN RAT STRIATAL NEURONS 1.055
CAFFEINE SENSITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST BUT NOT PRE-SYNAPTIC CHANGES IN RAT STRIATAL NEURON 1.048
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex 1.034
null 1.012
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 985
null 981
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 970
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 961
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats 932
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? 914
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment 880
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson’s disease 840
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease 835
null 830
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 817
null 801
Modulation of dopamine d1-mediated turning behavior and striatal c-fos expression by the substantia nigra 797
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation 784
Effect of MK 801 on priming of D-1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen 774
“Priming” to dopamine agonist-induced contralateral turning as model of non associative sensitization to the expression of the post-synaptic dopamine message 764
MPTP: Advances from an Evergreen Neurotoxin 753
Role of prefrontal cortex dopamine and noradrenaline circuitry in addiction 743
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 708
Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice 704
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders 698
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? 690
Nanocrystals as an effective strategy to improve Pomalidomide bioavailability in rodent 687
MPTP: advances from an evergreen neurotoxin 681
GABA(A) receptors mediate orexin-A induced stimulation of food intake. 658
Changes in GAD67 and peptides mRNA levels in specific populations of striatal efferent neurons following priming with dopamine agonists in 6-OHDA lesioned rats 650
Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice 643
Alterazioni nei livelli striatali di RNAm della GAD67, dinorfina e enkefalina, in seguito a priming con agonisti dopaminergici nel modello di morbo di parkinson della 6-ohda 634
Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease 621
Differential effect of priming with dopamine agonists on mrna for GAD-67, dynorphin and enkephalin in 6-OHDA lesioned rats 618
Expression offunctional leptin receptors in rodent leydig cells 614
Different patterns of behavior and gene expression induced by chronic L-DOPA and A2A antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 607
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 601
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease 557
Totale 165.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 218.405
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 218.405
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.972 0 465 470 646 618 417 493 409 759 912 869 914
2022/202314.219 1.057 1.774 1.717 1.115 966 1.524 863 1.000 1.004 1.130 1.452 617
2023/202413.719 605 638 656 772 1.377 2.227 2.265 999 562 976 1.216 1.426
2024/202520.375 2.774 3.665 4.834 2.900 1.350 1.690 1.859 175 258 249 256 365
2025/20267.331 461 274 760 574 479 581 1.680 494 514 827 472 215
2026/2027351 301 50 0 0 0 0 0 0 0 0 0 0
Totale 172.281